Trial Profile
A Randomized, Single-blind, Parallel Group ,Phase II Clinical Trial to Compare ReJoinTM (Autologous Adipose-derived Mesenchymal Progenitor Cells)to Sodium Hyaluronate Injection for the Patients With Knee Osteoarthritis Cartilage Defects
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Autologous adipose-derived mesenchymal stem cell therapy-AbelZeta Pharma (Primary) ; Hyaluronic acid
- Indications Cartilage disorders
- Focus Therapeutic Use
- Sponsors AbelZeta Pharma; Cellular Biomedicine Group
- 14 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Dec 2018 Planned End Date changed from 1 Dec 2016 to 1 Dec 2019.
- 14 Dec 2018 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2019.